Skip to main content
Have a personal or library account? Click to login
Barriers and Enablers to Guideline-Directed Prescribing for Heart Failure with Reduced Ejection Fraction: A Multi-Stakeholder Qualitative Study Cover

Barriers and Enablers to Guideline-Directed Prescribing for Heart Failure with Reduced Ejection Fraction: A Multi-Stakeholder Qualitative Study

Open Access
|Oct 2026
Read online

References

  1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. DOI: 10.1093/cvr/cvac013
  2. James S, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. DOI: 10.1016/S0140-6736(18)32279-7
  3. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: An updated review. Card Fail Rev. 2023;9:e11. DOI: 10.15420/cfr.2023.05
  4. Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: The PARADIGM-HF trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circ Heart Fail. 2018;11(4):e004745. DOI: 10.1161/CIRCHEARTFAILURE.117.004745
  5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717. DOI: 10.1056/NEJM199909023411001
  6. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. DOI: 10.1056/NEJMoa1911303
  7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. DOI: 10.1016/S0140-6736(99)04440-2
  8. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet. 1999;353(9146):9–13. DOI: 10.1016/S0140-6736(98)11181-9
  9. Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. JACC. 2021;77(11):1397–1407. DOI: 10.1016/j.jacc.2021.01.044
  10. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–128. DOI: 10.1016/S0140-6736(20)30748-0
  11. Tang AB, Ziaeian B, Butler J, Yancy CW, Fonarow GC. Global impact of optimal implementation of guideline-directed medical therapy in heart failure. JAMA Cardiol. 2024;9(12):1154–1158. DOI: 10.1001/jamacardio.2024.3023
  12. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032. DOI: 10.1161/CIR.0000000000001073
  13. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599–3726. DOI: 10.1093/eurheartj/ehab368
  14. Greene SJ, Ayodele I, Pierce JB, Khan MS, Lewsey SC, Yancy CW, et al. Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure. JACC Heart Fail. 2024;12(8):1365–1377. DOI: 10.1016/j.jchf.2024.03.001
  15. Vu HV, Bui TD, Do HA, Pham DDQ, Truong QB. Discrepancy between clinical guidelines and real-world management of heart failure with reduced ejection fraction at University Medical Center Ho Chi Minh City, Vietnam. BMC Cardiovasc Disord. 2025;25:506. DOI: 10.1186/s12872-025-04964-6
  16. Streett M, Jacobs A, Twilla J, Duncan K, Nadella G, Wells DA. Retrospective evaluation and analysis of pharmacoequity with guideline-directed medical therapy in heart failure with reduced ejection fraction (REAP-HF). Innov Pharm. 2025;16(1). DOI: 10.24926/iip.v16i1.6626
  17. Malgie J, Wilde MI, Clephas PRD, Emans ME, Koudstaal S, Schaap J, et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study. Eur J Heart Fail. 2024;26(7):1549–1560. DOI: 10.1002/ejhf.3267
  18. Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: A cohort study. Lancet Glob Health. 2018;6(9):e1008–1018. DOI: 10.1016/S2214-109X(18)30306-1
  19. Senanayake S, Lee ASY, Graves N, Win PPS, Lee A, Lau YH, et al. Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: Findings from a multicentre retrospective cohort study. BMJ Open. 2026;16(3):e107127. DOI: 10.1136/bmjopen-2025-107127
  20. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry. JACC. 2018;72(4):351–366. DOI: 10.1016/j.jacc.2018.04.070
  21. Lombardi CM, Ferreira JP, Carubelli V, Anker SD, Cleland JG, Dickstein K, et al. Geographical differences in heart failure characteristics and treatment across Europe: Results from the BIOSTAT-CHF study. Clin Res Cardiol. 2020;109(8):967–977. DOI: 10.1007/s00392-019-01588-7
  22. Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, et al. Heart failure drug treatment-inertia, titration, and discontinuation: A multinational observational study (EVOLUTION HF). JACC Heart Fail. 2023;11(1):1–14. DOI: 10.1016/j.jchf.2022.08.009
  23. Savarese G, Lindberg F, Christodorescu RM, Ferrini M, Kumler T, Toutoutzas K, et al. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. Eur J Heart Fail. 2024;26(6):1408–1418. DOI: 10.1002/ejhf.3214
  24. Steinman MA, Patil S, Kamat P, Peterson C, Knight SJ. A taxonomy of reasons for not prescribing guideline-recommended medications for patients with heart failure. Am J Geriatr Pharmacother. 2010;8(6):583–594. DOI: 10.1016/S1543-5946(10)80007-8
  25. Trinkley KE, Dafoe A, Malone DC, Allen LA, Huebschmann A, Khazanie P, et al. Clinician challenges to evidence-based prescribing for heart failure and reduced ejection fraction: A qualitative evaluation. J Eval Clin Pract. 2023;29(8):1363–1371. DOI: 10.1111/jep.13885
  26. Boyatzis RE. Transforming qualitative information: Thematic analysis and code development. Thousand Oaks, CA: Sage Publications; 1998.
  27. Crabtree BF, Miller WF. Using codes and code manuals: A template organizing style of interpretation. In Crabtree BF, Miller WF, editors. Doing Qualitative Research. 2nd ed. Thousand Oaks, CA: Sage Publications; 1999.
  28. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–1465. DOI: 10.1001/jama.282.15.1458
  29. NVivo [Computer software]. Version 15.2. Lumivero; 2025.
  30. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. DOI: 10.1093/intqhc/mzm042
  31. Kwok WKB, Ong HY, Lam SPC, Keong CC, Toh GLK, Yaw TS, et al. 2020 Clinical practice guidelines on the diagnosis and management of heart failure – A comprehensive updated guideline from the Heart Failure Society (Singapore) [Internet]. Singapore: HFSS; 2020. [cited 19 Aug 2026]. Available from: https://www.hfss.org.sg/wp-content/uploads/2018/07/Singapore-Heart-Failure-Guidelines-2020.pdf.
  32. O’Connor PJ, Sperl-Hillen JM, Johnson PE, Rush WA, Blitz G. Clinical inertia and outpatient medical errors. In Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in patient safety: From research to implementation (Volume 2: Concepts and methodology). Rockville, MD: Agency for Healthcare Research and Quality (US); 2005 Feb.
  33. Singapore Ministry of Health. Guide to MediSave usage for chronic disease management. Singapore: Ministry of Health; 2026 October.
  34. Philbin SE, Gleason LP, Persell SD, Walter E, Petito LC, Tibrewala A, et al. Barriers and facilitators to heart failure guideline-directed medical therapy in an integrated health system and federally qualified health centers: A thematic qualitative analysis. J Gen Intern Med. 2026;41(2):480–488. DOI: 10.1007/s11606-025-09515-5
  35. Cordwin DJ, Guidi J, Alhashimi L, Hummel SL, Koelling TM, Dorsch MP. Differences in provider approach to initiating and titrating guideline directed medical therapy in heart failure with reduced ejection fraction. BMC Cardiovasc Disord. 2024;24(1):247. DOI: 10.1186/s12872-024-03911-1
  36. Burgos LM, Duczynski MP, Coronel ML, Thierer J. Impact of a structured educational intervention on attitudes and practice of heart failure in Latin America. Arch Cardiol Mex. 2025;95(3):295–300. DOI: 10.24875/ACME.M25000630
  37. International Society of Nephrology. Optimization of RAASi Therapy Toolkit [Internet]. ISN; 2025. Available from: https://www.theisn.org/initiatives/toolkits/raasi-toolkit/.
  38. Sze S, Thaitirarot C, Krishnan S, Chan D, Nicolson W, Squire I, et al. Early and rapid initiation of quadruple therapy for heart failure with reduced ejection fraction: A real-world experience. Clinical Medicine. 2025;25(2):100296. DOI: 10.1016/j.clinme.2025.100296
  39. Savarese G, Lindberg F, Cannata A, Chioncel O, Stolfo D, Musella F, et al. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2024;26(6):1278–1297. DOI: 10.1002/ejhf.3295
  40. Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: A major issue to tackle. Heart Fail Rev. 2021;26(6):1359–1370. DOI: 10.1007/s10741-020-09979-z
  41. Zare-Kaseb A, Zeydi AE, Bakhtiari-Dovvombaygi H, Nazari AM. Effects of education based on teach-back methods on self-care and quality of life of the patients with heart failure: A systematic review. BMC Cardiovasc Disord. 2024;24:591. DOI: 10.1186/s12872-024-04264-5
  42. Jaarsma T, Strömberg A, Mårtensson J, Dracup K. Development and testing of the European Heart Failure Self-Care Behaviour Scale. Eur J Heart Fail. 2003;5(3):363–370. DOI: 10.1016/S1388-9842(02)00253-2
  43. Heart Failure Association of the European Society of Cardiology. What heart failure is – and what it can mean for everyday life [Internet]. ESC. Available from: https://www.heartfailurematters.org/en_GB/Understanding-heart-failure/What-is-heart-failure.
  44. Mussi CM, Ruschel K, de Souza EN, Lopes ANM, Trojahn MM, Paraboni CC, et al. Home visit improves knowledge, self-care and adhesion in heart failure: Randomized clinical trial HELEN-I. Rev Lat Am Enfermagem. 2013;21(spe):20–28. DOI: 10.1590/S0104-11692013000700004
  45. Ruiz-Bustillo S, Vicente M, Ruiz-Rodriguez P, Linás-Alonso AM, Valdivielso-Moré S, Farré N, et al. Effectiveness of a nurse-led telemedicine-based program for pharmacological and prognostic optimization of patients with heart failure and reduced ejection fraction: The MAR-HF-Titration study. Eur J Cardiovasc Nurs. 2025;24(8):1365–1374. DOI: 10.1093/eurjcn/zvaf161
  46. Bekelman DB, Feser W, Morgan B, Welsh CH, Parsons EC, Paden G, et al. Nurse and social worker palliative telecare team and quality of life in patients with COPD, heart failure, or interstitial lung disease: The ADAPT randomized clinical trial. JAMA. 2024;331(3):212–223. DOI: 10.1001/jama.2023.24035
  47. Teo SH, Chew EAL, Ng DWL, Tang WE, Koh GCH, Teo VHY. Implementation and use of technology-enabled blood pressure monitoring and teleconsultation in Singapore’s primary care: A qualitative evaluation using the socio-technical systems approach. BMC Prim Care. 2023;24:71. DOI: 10.1186/s12875-023-02014-8
DOI: https://doi.org/10.5334/gh.1596 | Journal eISSN: 2211-8179 | Journal ISSN: 2211-8160
Language: English
Page range: 79 - 79
Submitted on: Jul 1, 2026
Accepted on: Oct 13, 2026
Published on: Oct 30, 2026
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services

© 2026 Thin Mar Win, Audry Shan Yin Lee, Sameera Senanayake, Nicholas Graves, Sanjeewa Kularatna, Raymond Ching Chiew Wong, Seet Yoong Loh, Tan Yuyang, Huang Weiliang, Chow Weien, Jeanne Shan Yin Ong, Peck Kah Hua, Derek J. Hausenloy, Mark Yan-Yee Chan, Khung-Keong Yeo, Kheng Leng David Sim, Sungwon Yoon, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.